From NAFLD to NASH and HCC: Pathogenetic Mechanisms and Therapeutic Insights

E-ISSN： 1873-4286|19|29|5239-5249

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.19, Iss.29, 2013-09, pp. : 5239-5249

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Current and Future Therapeutic Strategies in NAFLD

Current Pharmaceutical Design, Vol. 16, Iss. 17, 2010-06 ,pp. : 1958-1962

Bentham Science Publishers

Access to resources Recommend Favorite

Fibrinolysis: The Key to New Pathogenetic Mechanisms

Current Medicinal Chemistry, Vol. 15, Iss. 9, 2008-04 ,pp. : 923-929

Bentham Science Publishers

Access to resources Recommend Favorite

Genetic Predisposition in NAFLD and NASH: Impact on Severity of Liver Disease and Response to Treatment

Current Pharmaceutical Design, Vol. 19, Iss. 29, 2013-09 ,pp. : 5219-5238

Bentham Science Publishers

Access to resources Recommend Favorite

Toward a Biochemical Diagnosis of NASH: Insights From Pathophysiology For Distinguishing Simple Steatosis From Steatohepatitis

Current Medicinal Chemistry, Vol. 18, Iss. 5, 2011-02 ,pp. : 725-732

Bentham Science Publishers

Access to resources Recommend Favorite

The CBS/CSE system: a potential therapeutic target in NAFLD?

Canadian Journal of Physiology and Pharmacology, Vol. 93, Iss. 1, 2015-01 ,pp. : 1-11

NRC Research Press

Access to resources Recommend Favorite